Compare · NVO vs ONC
NVO vs ONC
Side-by-side comparison of Novo Nordisk A/S (NVO) and BeOne Medicines Ltd. (ONC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ONC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 6.1x ONC ($30.11B).
- Over the past year, NVO is down 45.7% and ONC is up 2.7% - ONC leads by 48.3 points.
- ONC has been more active in the news (10 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 6 for ONC).
- Company
- Novo Nordisk A/S
- BeOne Medicines Ltd.
- Price
- $41.01-4.51%
- $270.74+0.26%
- Market cap
- $183.15B
- $30.11B
- 1M return
- -10.44%
- -14.68%
- 1Y return
- -45.66%
- +2.68%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 8
- 10
- Recent ratings
- 25
- 6
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest ONC
- SEC Form 144 filed by BeOne Medicines Ltd.
- Director Yi Qingqing sold $65,596 worth of American Depositary Shares (235 units at $279.13), closing all direct ownership in the company (SEC Form 4) (for withholding tax)
- BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
- BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
- Director Riva Alessandro sold $65,617 worth of American Depositary Shares (212 units at $309.51), closing all direct ownership in the company (SEC Form 4) (tax liability)
- Director Dugan Margaret sold $65,636 worth of American Depositary Shares (212 units at $309.60), closing all direct ownership in the company (SEC Form 4) to cover taxes
- Director Sanders Corazon (Corsee) D. sold $65,633 worth of American Depositary Shares (212 units at $309.59), closing all direct ownership in the company (SEC Form 4) to cover taxes
- BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
- Director Baker Bros. Advisors Lp sold $261,981 worth of Ordinary Shares (10,998 units at $23.82) (SEC Form 4) to satisfy withholding tax
- BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference